The pharmacokinetics of promethazine hydrochloride after administration of rectal suppositories at three dosage strengths and oral syrup were studied. The study had an open-label, randomized ...
The NMR and Drug Metabolism Core has developed rapid and efficient approaches to investigate metabolism, metabolic stability, pharmacokinetics (PK), and chemical structure identification of small ...
Developing new drugs to treat illnesses has typically been a slow and expensive process. However, a team of researchers at ...
Hosted on MSN8mon
EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use DisorderThe pharmacokinetics study was initiated in June 2024 and is expected to be completed during the fourth quarter of 2024. The single-center open-label relative bioavailability and dose ...
The purpose of this study was to evaluate the pharmacokinetics of intranasal hydromorphone hydrochloride (HCl) in patients with vasomotor rhinitis. Methods: Ten patients completed the randomised ...
Quantification and prediction of human fetal (-)-Δ 9-tetrahydrocannabinol/(±)-11-OH-Δ 9-tetrahydrocannabinol exposure during pregnancy to inform fetal cannabis ...
We have previously demonstrated an apparent decrease in renal tubular secretion and an increase in plasma half-life for furosemide (F) in VLBW infants. To pharmacokinetically characterize ...
Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamicsClinical data from this trial, together with ...
The Phase 2a study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of VENT-02 over a 28-day ...
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment First ...
Merck has shared data from the pivotal Phase 3 trial evaluating the subcutaneous administration of pembrolizumab together ...
A groundbreaking Phase 1 study suggests that once-yearly intramuscular lenacapavir could be a promising option for HIV PrEP.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results